levodopa/carbidopa ER (WD-1603) / China NT Pharma - LARVOL DELTA

A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Shanghai WD Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Apr 2026

Trial completion • Trial completion date

Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Shanghai WD Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease (clinicaltrials.gov) - P2 | N=40 | Completed | Sponsor: Shanghai WD Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Shanghai WD Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Shanghai WD Pharmaceutical Co., Ltd.

New P1 trial

A Phase II Randomized, Parallel, Double-blind, Placebo-controlled Study of the Efficacy and Safety of WD-1603 in Subjects with Parkinson's Disease (MDS Congress 2025) - "WD-1603 shows promising efficacy in a dose-dependent manner, providing significant improvements in efficacy as early as by Day 14. An FI of 1.19 indicates minimal peak-to-trough fluctuation in plasma levodopa levels, suggesting that WD-1603 provides a relatively consistent delivery of levodopa over time. This stability could contribute to sustained efficacy and potentially fewer motor fluctuations."

Clinical • P2 data • CNS Disorders • Movement Disorders • Parkinson's Disease

Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions (clinicaltrials.gov) - P1; N=15; Recruiting; Sponsor: Shanghai WD Pharmaceutical Co., Ltd.

Clinical • New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: Shanghai WD Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: Shanghai WD Pharmaceutical Co., Ltd.

Clinical • New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

PK Study of WD-1603 in Healthy Subjects (clinicaltrials.gov) - P1; N=8; Recruiting; Sponsor: Hong Kong WD Pharmaceutical Co., Limited

Clinical • New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions (clinicaltrials.gov) - P1; N=8; Not yet recruiting; Sponsor: Hong Kong WD Pharmaceutical Co., Limited

Clinical • New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects (clinicaltrials.gov) - P1; N=8; Recruiting; Sponsor: Hong Kong WD Pharmaceutical Co., Limited

Clinical • New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease